7.	Stock-Based Compensation

The compensation costs that have been charged against income for the 13 weeks and 26 weeks ended August 3, 2019 and August 4, 2018 were as follows (in thousands):

	13 Weeks Ended				26 Weeks Ended
	August 3, 2019		August 4, 2018		August 3, 2019		August 4, 2018
Stock-based compensation expense by type:
Stock options	$	-	$	17	$	92	$	177
Restricted stock units		354		849		716		2,372
Employee stock purchases		21		28		51		57
Director deferred compensation		24		23		47		47
Total stock-based compensation expense		399		917		906		2,653
Income tax benefit recognized		89		225		203		593
Stock-based compensation expense, net of income tax	$	310	$	692	$	703	$	2,060

Expense for restricted stock units is shown net of forfeitures of $0.5 million and $1.8 million for the 13 weeks and 26 weeks ended August 3, 2019, respectively. Expense for restricted stock units is shown net of forfeitures of $0.1 million for both the 13 weeks and 26 weeks ended August 4, 2018.

In the 13 weeks and 26 weeks ended August 3, 2019 and August 4, 2018, we granted the following equity awards:

	13 Weeks Ended				26 Weeks Ended
	August 3, 2019		August 4, 2018		August 3, 2019		August 4, 2018
Stock options		--		--		16,798		19,994
Restricted stock unit awards		31,573		--		222,594		169,572
Performance-based restricted stock unit awards		--		--		34,300		44,700
Deferred stock units		1,288		1,023		2,315		2,002

At August 3, 2019, the total compensation costs related to nonvested restricted stock unit awards not yet recognized was $6.7 million and the weighted-average period over which such awards are expected to be recognized was 2.7 years. There were no compensation costs related to nonvested stock options at August 3, 2019.

Under the 2012 Non-Employee Director Equity Plan (2012 Plan), no shares of our common stock were awarded during the 13 weeks ended August 3, 2019 and August 4, 2018. A total of 13,858 and 4,435 shares of our common stock were awarded during the 26 weeks ended August 3, 2019 and August 4, 2018, respectively, as part of the annual equity award to directors in the first quarter.

No stock options were granted during the 13 weeks ended August 3, 2019 and August 4, 2018. The weighted-average grant date fair value of stock options granted during the 26 weeks ended August 3, 2019 and August 4, 2018 was $5.46 and $7.15 per share, respectively.

The number of shares purchased, the average price per share and the weighted-average grant date fair value of shares purchased through our employee stock purchase plan were as follows:

	13 Weeks Ended				26 Weeks Ended
	August 3, 2019		August 4, 2018		August 3, 2019		August 4, 2018
Shares purchased		5,628		5,777		15,553		12,331
Average price per share	$	15.47	$	19.47	$	13.35	$	18.34
Weighted average fair value at grant date	$	5.20	$	5.35	$	3.89	$	4.91